Windtree Therapeutics, Inc. (WINT) Earnings History
Annual and quarterly earnings data from 1995 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export WINT earnings history in CSV or JSON format
Free sign-in required to download data
Windtree Therapeutics, Inc. (WINT) Earnings Overview
As of March 2, 2026, Windtree Therapeutics, Inc. (WINT) reported trailing twelve-month net income of -$41M, reflecting +1.0% year-over-year growth. The company earned $-1531.62 per diluted share over the past four quarters.
Looking at the long-term picture, WINT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 1996.
Windtree Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including UTHR ($1.33B net income, 0.4% margin), ZLAB (-$176M net income, -0.4% margin), AMRN (-$86M net income, -0.4% margin), WINT has comparable earnings metrics. Compare WINT vs UTHR →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
30 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$5M | +73.0% | -$25M | $-104.35 | - | - |
| 2023 | -$20M | +48.2% | -$18M | $-4711.54 | - | - |
| 2022 | -$39M | +42.0% | -$41M | $-56011.00 | - | - |
| 2021 | -$68M | -123.4% | -$77M | $-122924.00 | - | - |
| 2020 | -$30M | -10.2% | -$30M | $-93616.00 | - | - |
| 2019 | -$27M | -33.8% | -$25M | $-113138.00 | -13876.3% | -12572.2% |
| 2018 | -$21M | -11.3% | -$16M | $-999999.00 | -1148.4% | -905.8% |
| 2017 | -$18M | +53.3% | -$23M | $-999999.00 | -1242.2% | -1518.4% |
| 2016 | -$39M | +28.4% | -$38M | $-999999.00 | -1933.9% | -1862.7% |
| 2015 | -$55M | -25.2% | -$40M | $-999999.00 | -5589.7% | -4035.9% |
See WINT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs WINT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare WINT vs AGIO
See how WINT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is WINT growing earnings?
WINT EPS of $-1531.62 reflects slowing growth at +1.0%, below the 5-year CAGR of N/A. TTM net income is $-41M. Expansion rate has moderated.
What are WINT's profit margins?
Windtree Therapeutics, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are WINT's earnings?
WINT earnings data spans 1995-2024. The current earnings trend is +1.0% YoY. Historical data enables comparison across business cycles.